Dr. Arshad Ayyaz stood in his University of Calgary lab, staring at the data: 100% tumor eradication in mice—something nearly unheard of in colon cancer research. For two decades, Ayyaz has studied thehpp the gut’s intricate biology, but this moment was different. His team had done more than slow a tumor—they had unmasked it. By deleting a single gene, NOTUM, they stripped colon cancer of its ability to hide from the immune system, turning immunotherapy from a failed promise into a potent weapon.
Colon cancer is one of the most common and deadly cancers worldwide, yet it has stubbornly resisted immunotherapy, a treatment that has revolutionized outcomes for melanoma, lung cancer, and others. Only about 15% of colon cancer patients respond, leaving the vast majority with limited options. The reason, Ayyaz and his team discovered, lies in a protein secreted by treatment-resistant tumors—one that actively disguises the cancer as harmless tissue. “It’s like an invisibility cloak,” Ayyaz says. “The immune system walks right past.”
The breakthrough came when the researchers used gene-editing to knock out NOTUM, the gene responsible for producing this deceptive protein. In mouse models, the results were stunning. Without NOTUM, the tumors became visible to the immune system. When combined with immunotherapy, the tumors disappeared completely in every subject. Even more remarkably, tumors shrank without treatment—proof that the body’s own defenses could now recognize and attack the cancer.
Published in Cell Reports Medicine in 2026, the study identifies a new mechanism of immune resistance in microsatellite stable colorectal cancer, the most common form of the disease. The implications extend beyond colon cancer: solid tumors in the pancreas, lung, and elsewhere also resist immunotherapy, possibly through similar cloaking strategies. Ayyaz believes this discovery could open doors to rethinking how we approach treatment-resistant cancers.
While clinical applications are still years away, the findings have ignited hope. This isn’t about boosting the immune system’s strength—it’s about removing the tumor’s deception. “We’re not making the immune system better,” Ayyaz explains. “We’re stopping the cancer from lying.” As research continues, the NOTUM gene may become a critical target, not just for colon cancer, but for a range of stubborn solid tumors. For a field often measured in incremental gains, this is a leap—one that began with a single gene and a scientist who refused to look away.